Observational studyFrontiers in endocrinology2026
Effects of SGLT-2 inhibitors and GLP-1 receptor agonists on liver function in patients with non-alcoholic fatty liver disease and type 2 diabetes.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The goal was having the comparisons be direct when it came to seeing how much of a help the sodium-glucose co transporter - 2 inhibitors (SGTL2is) compared to the glucagon-like peptide-1 receptor agonists (GLP-1RAs) were in regard to how the liver enzymes performed within people having type 2 diabetes (T2D) along with nonalcoholic fatty liver disease (NAFLD), a condition characterized by excessive fat accumulation in the liver without alcohol overconsumption. Methods: A total of 705 subjects with T2DM and NAFLD at time of first SGLT2is (n=381) or GLP-1RAs (n=324) enrolment in this multicentre posterior cohort study from 01/2020-12/2024. Baseline characteristics were made equivalent via PSM via a 1: 1 NN match and a 0. 2 SD match clamp. The main measurement was the difference in alanine amino transferase (ΔALT) and aspartate aminotransferase (ΔAST) from the beginning and 6 months. And other result was about the change in metabolic parametres. The independent predictors of liver-enzyme change came from the multivariate linear regression analysis. Results: After PSM, 243 well-matched pairs were successfully identified, with baseline characteristics acceptably balanced (standardized differences <0.2 for all covariates and <0.1 for most covariates). In the matched cohort, SGLT2is treatment was associated with significantly greater reductions in ALT (ΔALT: -10.55 ± 12.66 vs. -7.28 ± 15.34 U/L, p=0.011) and AST (ΔAST: -7.68 ± 10.07 vs. -5.18 ± 11.04 U/L, p=0.010) compared to GLP-1RAs treatment. No significant differences were observed for changes in GGT, body weight, glycemic control, or lipid profiles between groups. Multivariable regression analysis revealed that SGLT2is treatment was independently associated with reductions in both ALT (β = -3.34, p=0.009) and AST (β = -2.32, p=0.016). Weight change was independently associated with AST reduction (β = 0.22, p=0.016) but not with ALT reduction. Conclusion: SGLT2is were associated with greater ALT and AST reductions than GLP-1RAs in T2D patients with NAFLD, with ALT improvement independent of weight loss, suggesting potential direct hepatoprotective effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.